Cardiff Oncology (NASDAQ:CRDF – Get Rating) had its target price reduced by HC Wainwright from $22.00 to $14.00 in a report issued on Friday morning, The Fly reports. They currently have a buy rating on the stock.
Several other analysts also recently weighed in on CRDF. Piper Sandler dropped their target price on shares of Cardiff Oncology from $7.00 to $5.00 and set an overweight rating for the company in a report on Tuesday, September 13th. Robert W. Baird dropped their price target on shares of Cardiff Oncology from $9.00 to $6.00 and set an outperform rating for the company in a research note on Monday, August 29th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of Buy and a consensus price target of $9.75.
Get
Cardiff Oncology alerts:
Cardiff Oncology Stock Performance
CRDF stock opened at $1.73 on Friday. The firm has a market cap of $74.92 million, a PE ratio of -1.94 and a beta of 1.38. The firm's 50 day moving average price is $2.51 and its 200-day moving average price is $2.13. Cardiff Oncology has a one year low of $1.13 and a one year high of $7.63.
Cardiff Oncology (NASDAQ:CRDF – Get Rating) last posted its earnings results on Thursday, August 4th. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.01. Cardiff Oncology had a negative net
margin of 9,841.41% and a negative return on equity of 28.82%. The firm had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.08 million. Equities research analysts predict that Cardiff Oncology will post -1.04 EPS for the current fiscal year.
Insider Buying and Selling
In other news, CFO James E. Levine bought 30,000 shares of the stock in a transaction that occurred on Friday, September 16th. The stock was purchased at an average price of $1.56 per share, for a total transaction of $46,800.00. Following the completion of the purchase, the chief financial officer now owns 60,000 shares in the company, valued at approximately $93,600. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 3.50% of the company's stock.
Hedge Funds Weigh In On Cardiff Oncology
A number of institutional investors and hedge funds have recently modified their holdings of CRDF. Quantbot Technologies LP purchased a new stake in Cardiff Oncology in the first quarter valued at $28,000. LPL Financial LLC lifted its position in Cardiff Oncology by 17.9% in the second quarter. LPL Financial LLC now owns 26,384 shares of the company's stock valued at $58,000 after acquiring an additional 3,998 shares during the last quarter. XTX Topco Ltd purchased a new stake in Cardiff Oncology in the first quarter valued at $62,000. Price T Rowe Associates Inc. MD lifted its position in Cardiff Oncology by 69.9% in the second quarter. Price T Rowe Associates Inc. MD now owns 36,500 shares of the company's stock valued at $80,000 after acquiring an additional 15,020 shares during the last quarter. Finally, GSA Capital Partners LLP purchased a new stake in Cardiff Oncology in the fourth quarter valued at $93,000. Institutional investors and hedge funds own 20.70% of the company's stock.
Cardiff Oncology Company Profile
(Get Rating)
Cardiff Oncology, Inc, a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.
Featured Articles
- Get a free copy of the StockNews.com research report on Cardiff Oncology (CRDF)
- Oracle's Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
Receive News & Ratings for Cardiff Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiff Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
